Sign in

    Nick LorussoTD Cowen

    Nick Lorusso's questions to Iovance Biotherapeutics Inc (IOVA) leadership

    Nick Lorusso's questions to Iovance Biotherapeutics Inc (IOVA) leadership • Q2 2025

    Question

    Nick Lorusso, on for Tyler Van Buren at TD Cowen, asked for an update on how Amtagvi infusions are tracking quarter-to-date and requested new metrics on ATC prescribing depth, such as the percentage of centers that have infused one or more patients.

    Answer

    Chief Commercial Officer Dan Kirby stated that while demand remains strong, it is company policy not to comment on intra-quarter infusion numbers. He confirmed that prescribing depth at ATCs has increased but noted that the company would no longer provide specific metrics on the percentage of centers hitting certain infusion thresholds.

    Ask Fintool Equity Research AI